Litigation Details for AbbVie Inc. v. Gilead Sciences Inc. (D. Del. 2014)

AbbVie Inc. v. Gilead Sciences Inc. (D. Del. 2014)

Docket	1:14-cv-00379	Date Filed	2014-03-25
Court	District Court, D. Delaware	Date Terminated	2016-08-24
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	Plaintiff	Referred To
Patents	8,680,106; 8,685,984
Link to Docket	External link to docket

Details for AbbVie Inc. v. Gilead Sciences Inc. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-03-25				External link to document

AbbVie Inc. v. Gilead Sciences Inc. Litigation Summary and Patent Analysis, 1:14-cv-00379

Last updated: August 2, 2026

AbbVie Inc. v. Gilead Sciences Inc., No. 1:14-cv-00379, was a Delaware patent dispute over hepatitis C virus treatments, including Gilead’s Sovaldi and Harvoni products. AbbVie alleged that Gilead’s sofosbuvir-based products infringed AbbVie patent claims covering HCV antiviral compounds and treatment methods. The case did not produce a generic-entry settlement or a damages award for AbbVie. The asserted claims were ultimately held invalid, including on written-description grounds, and the Federal Circuit affirmed the adverse judgment. The litigation therefore ended without a royalty stream, license payment, or commercial restriction on Gilead’s products.

What patents did AbbVie assert against Gilead?

AbbVie asserted patents directed to HCV antiviral compounds and their use in treating HCV infection. The principal patents associated with the action included U.S. Patent No. 8,685,984 and related continuation-family patents, including U.S. Patent No. 9,090,733.

Patent	General subject matter	Plaintiff	Relevance to case
U.S. 8,685,984	HCV antiviral compounds and pharmaceutical uses	AbbVie affiliates	Asserted against Gilead’s HCV products
U.S. 9,090,733	Related HCV compound and treatment claims	AbbVie affiliates	Later invalidity and written-description issues
Related continuation-family patents	HCV compounds, compositions and treatment methods	AbbVie affiliates	Supported AbbVie’s broader patent position

The patents claimed chemical structures and therapeutic applications within the HCV treatment field. The dispute was not limited to a conventional formulation patent. It concerned the scope of genus claims covering classes of antiviral compounds and whether the patent specifications adequately described the full claimed scope.

The asserted patents were not patents on a biologic product. They covered small-molecule antiviral chemistry. Biosimilar law therefore had no direct application.

Which Gilead products were accused of infringement?

AbbVie targeted Gilead’s commercially important sofosbuvir-based HCV products.

Product	Active ingredient or combination	FDA milestone	Role in litigation
Sovaldi	Sofosbuvir	FDA approved December 2013	Accused product
Harvoni	Ledipasvir/sofosbuvir	FDA approved October 2014	Accused product
Other sofosbuvir-based products	Sofosbuvir combinations	Later FDA approvals	Relevant to commercial exposure

Sovaldi is a nucleotide analog polymerase inhibitor. Harvoni combines sofosbuvir with ledipasvir, an NS5A inhibitor. Gilead’s products were approved for treatment of chronic HCV infection and generated substantial revenue during the period of the litigation [U.S. Food and Drug Administration, 2013, 2014].

AbbVie’s case was commercially significant because it implicated Gilead’s core HCV franchise. It also occurred while AbbVie was developing and commercializing its competing Viekira Pak regimen.

What was the procedural history of AbbVie v. Gilead?

AbbVie filed the action in the U.S. District Court for the District of Delaware in 2014 under docket number 1:14-cv-00379. The case was assigned to Judge Leonard P. Stark.

The litigation focused on claim construction, infringement, validity, and the adequacy of AbbVie’s written description. The dispute moved beyond a simple question of whether Gilead’s products fell within the literal scope of the asserted claims. Gilead challenged whether AbbVie’s patent specifications demonstrated possession of the breadth of the claimed chemical genus as of the priority date.

The case ultimately produced an adverse judgment against AbbVie on patent validity. The Federal Circuit affirmed the result, holding that the asserted claims were invalid for lack of written description. The appellate decision applied the established rule that a patent specification must demonstrate possession of the claimed invention across the full scope of a genus claim, not merely disclose a research objective or a limited number of representative species.

Why did the court find AbbVie’s patent claims invalid?

The central legal issue was written description under 35 U.S.C. §112(a).

AbbVie claimed a broad class of HCV compounds. The court assessed whether the specification adequately disclosed representative members of the claimed genus and whether the disclosed compounds shared sufficient identifying characteristics to show possession of the entire claimed class.

The court’s analysis focused on the gap between:

1. The number and structural diversity of compounds covered by the claims; and
2. The number and characteristics of compounds actually disclosed in the specification.

The Federal Circuit treated the claims as broad genus claims. It concluded that the patent did not adequately describe the claimed genus as a whole. The disclosure identified certain compounds and research directions, but it did not sufficiently demonstrate possession of the full breadth of the claimed chemical class.

This distinction matters in pharmaceutical patent litigation. A specification can disclose a commercially useful species without adequately supporting a broad genus claim that covers many unmade and structurally different compounds. The result is especially important for medicinal chemistry patents, where small structural changes can materially affect potency, selectivity, pharmacokinetics, toxicity, and clinical performance.

The decision did not establish that all broad pharmaceutical genus claims are invalid. It applied the written-description requirement to the specific scope and disclosure of AbbVie’s patents.

Did Gilead infringe AbbVie’s patents?

The ultimate outcome did not impose infringement liability on Gilead. Because the asserted claims were held invalid, AbbVie could not obtain an enforceable infringement judgment or damages award based on those claims.

The case therefore ended differently from major HCV disputes in which patentees obtained large jury verdicts or settlements. In Merck & Co. v. Gilead Sciences, Inc., for example, a separate dispute concerning sofosbuvir technology resulted in a major damages award before later appellate developments. AbbVie’s action did not produce a comparable recovery.

Was there a Paragraph IV challenge?

No. The case was not a Hatch-Waxman Paragraph IV action.

A Paragraph IV dispute arises when a generic applicant files an ANDA certifying that an Orange Book-listed patent is invalid, unenforceable, or not infringed. AbbVie’s lawsuit was a branded-company patent action against another branded pharmaceutical company. Gilead was not seeking FDA approval to market a generic version of an AbbVie product.

The litigation was therefore based on conventional patent infringement claims under 35 U.S.C. §271, not on an ANDA certification.

What was the Orange Book status of the disputed patents?

The litigation did not create a generic launch date or an ANDA stay. Gilead’s FDA-approved products remained branded products, and the case did not suspend or condition their FDA approvals.

Sovaldi and Harvoni were listed in the FDA’s Orange Book with Gilead-related patent information. The AbbVie patents asserted in the Delaware case should not be treated as creating a statutory Orange Book stay against Gilead. Their practical effect would have depended on enforceability and infringement findings, not on the Hatch-Waxman approval framework [FDA, 2024].

The invalidity judgment reduced the value of the asserted AbbVie patents as potential barriers to Gilead’s HCV products. It did not remove the FDA approvals for Sovaldi or Harvoni.

When did the relevant patent protection expire?

The relevant patent-family expiration dates were generally tied to priority filings in the late 2000s. For a conventional U.S. utility patent, the base term is generally 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory adjustments.

Because the asserted claims were held invalid, their practical exclusivity ended with the judgment rather than at the nominal expiration date. A patent can have years remaining on its term but provide no enforceable exclusivity if its claims are invalidated.

Exclusivity issue	Effect in this case
Patent term	Relevant family had a nominal term extending into the late 2020s, subject to adjustments
Written-description validity	Claims held invalid
FDA exclusivity	Not eliminated by this patent case
Generic exclusivity	No Paragraph IV launch framework applied
Enforceable exclusion	No enforceable AbbVie exclusion remained for the invalid claims

Did the parties reach a licensing deal or settlement?

The litigation did not result in a publicly reported license or settlement requiring Gilead to pay AbbVie royalties on Sovaldi or Harvoni.

This is commercially important. A settlement could have converted AbbVie’s patent position into a recurring royalty or delayed competition. The judgment instead left Gilead free to continue commercializing its approved products without an AbbVie payment obligation arising from this case.

The case should also be distinguished from commercial arrangements involving other HCV patents, technology acquisitions, or licenses. Those transactions do not establish that Gilead licensed the AbbVie patents asserted in 1:14-cv-00379.

How strong was AbbVie’s HCV patent estate?

AbbVie’s estate had meaningful subject-matter breadth but a material validity weakness in the asserted genus claims.

Strengths

• The patents were directed to commercially important HCV antiviral chemistry.
• The claims covered compound classes and treatment applications rather than only a narrow manufacturing process.
• The patents were asserted against high-revenue branded products.
• The estate was supported by continuation filings and related patent-family activity.

Weaknesses

• Broad genus claims created written-description exposure.
• The disclosed examples did not adequately represent the full claimed chemical scope.
• The litigation strategy depended on enforcing claims broad enough to reach Gilead’s products.
• Invalidity eliminated the value of the asserted claims regardless of commercial importance.

The case illustrates a recurring risk in pharmaceutical patent portfolios: broad claims can provide substantial blocking potential if valid, but they face heightened scrutiny when the specification discloses only a small number of compounds relative to the claimed genus.

What commercial impact did the case have?

The direct financial impact on AbbVie was the loss of a potential damages or royalty recovery from Gilead’s HCV franchise. No reported judgment transferred a portion of Sovaldi or Harvoni revenue to AbbVie.

The indirect commercial impact was more significant. Gilead retained freedom to commercialize its leading HCV products without a case-specific injunction or royalty burden. AbbVie had to compete through its own Viekira Pak and later HCV products rather than through enforcement leverage against Gilead.

The case also reduced the value of the related AbbVie patent estate in licensing negotiations involving sofosbuvir-era HCV therapies. Patent invalidity findings are relevant to continuation patents, prosecution strategy, freedom-to-operate analysis, and settlement valuation, although they do not automatically invalidate every related patent or claim.

What generic-entry risks resulted from the case?

The decision did not itself authorize an immediate generic launch. Gilead’s products were branded, and generic entry remained subject to Gilead’s own valid patents, regulatory exclusivities, manufacturing capabilities, and other market barriers.

The case removed one potential AbbVie enforcement route. It did not resolve:

• The validity of every Gilead patent;
• The validity of every AbbVie HCV patent;
• Orange Book patents covering each Gilead product;
• FDA regulatory exclusivity periods;
• Manufacturing and supply-chain barriers;
• Separate patent disputes involving sofosbuvir or related HCV compounds.

For generic manufacturers, the relevant conclusion is narrower: AbbVie could not use the invalidated claims in this action to block Gilead’s products or demand compensation.

How does AbbVie v. Gilead compare with Merck v. Gilead?

Issue	AbbVie v. Gilead	Merck v. Gilead
Court action	D. Del., No. 1:14-cv-00379	Separate HCV patent litigation
Core technology	HCV compound and treatment claims	Sofosbuvir-related HCV technology
Outcome	Claims held invalid; no AbbVie damages recovery	Large damages verdict in separate litigation
Key legal issue	Written description and genus scope	Infringement, validity and damages
Commercial result	Gilead retained freedom to market products	Separate judgment and later appellate developments
Relevance to Orange Book	No Paragraph IV case	Also distinct from a conventional ANDA challenge

The two cases should not be combined in portfolio or valuation analysis. They involved different patents, parties’ theories, and outcomes.

Key Takeaways

• AbbVie sued Gilead in Delaware in 2014 over HCV antiviral patents.
• The accused products included Sovaldi and Harvoni.
• The case concerned branded-company patent infringement, not a Paragraph IV generic challenge.
• AbbVie’s broad HCV genus claims were held invalid for lack of written description.
• The Federal Circuit affirmed the adverse result.
• AbbVie received no reported damages award, royalty, or license payment from the case.
• Gilead retained the ability to commercialize its approved HCV products.
• The ruling weakened the asserted AbbVie HCV estate but did not automatically invalidate every related patent.
• Biosimilar risk was not relevant because Sovaldi and Harvoni are small-molecule drugs.
• The case is distinct from Merck’s separate HCV patent litigation against Gilead.

FAQs About AbbVie Inc. v. Gilead Sciences Inc.

What was the docket number for AbbVie v. Gilead?

The case was filed in the U.S. District Court for the District of Delaware as No. 1:14-cv-00379.

Did AbbVie win money from Gilead?

No. The asserted claims were held invalid, and AbbVie did not obtain a reported damages award or royalty judgment from the case.

Did the case stop sales of Sovaldi or Harvoni?

No. The litigation did not result in an injunction blocking Gilead’s sales of Sovaldi or Harvoni.

Did Gilead settle the AbbVie HCV patent case?

There was no publicly reported license or royalty settlement requiring Gilead to pay AbbVie for the accused products in this action.

Does the decision invalidate all AbbVie HCV patents?

No. The judgment applied to the asserted claims and does not automatically invalidate every patent, continuation, or claim in AbbVie’s broader HCV portfolio.

References

AbbVie Inc. v. Gilead Sciences, Inc., No. 1:14-cv-00379, U.S. District Court for the District of Delaware.

AbbVie Inc. v. Gilead Sciences, Inc., 3 F.4th 1324 (Fed. Cir. 2021).

U.S. Food and Drug Administration. (2013). FDA approves first drug to treat hepatitis C genotype 2 and 3 infections.

U.S. Food and Drug Administration. (2014). FDA approves first combination pill to treat hepatitis C.

U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.